Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05322148 · ClinicalTrials.gov registry record · Phase 3
Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization
A Phase 3 study, sponsored by Research Insight.
- Completed
- Registry status
- Phase 3
- Development phase
- 59
- Enrollment target
NCT05322148: Completed Phase 3 study, sponsored by Research Insight.
NCT05322148 is a Phase 3 study that has completed, run by Research Insight. The registered enrollment target is 59 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05322148, a Phase 3 study, has completed, sponsored by Research Insight.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 59 participants
- Enrollment target
Study Summary
The CLEAN Study: Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization-A Prospective Cohort Study of Combination Therapy in the Treatment of Dry Eye
Primary Outcome
Change in corneal higher order aberrations after 14 days and 28 days of treatment
Interventions
- DRUG Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2022-06-03 |
| Est. Completion | 2022-11-21 |
| Phase | Phase 3 |
What the finished NCT05322148 record still lists
NCT05322148 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free is the first listed.
NCT05322148 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05322148 about?
NCT05322148 is a clinical study titled "Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization". The CLEAN Study: Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization-A Prospective Cohort Study of Combination Therapy in the Treatment of Dry Eye
What is the current status of trial NCT05322148?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 59 participants. The study started on 2022-06-03. Estimated completion is 2022-11-21.
What interventions are being tested in trial NCT05322148?
The interventions under investigation include: Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free (DRUG).
Who is sponsoring clinical trial NCT05322148?
This trial is sponsored by Research Insight, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05322148's enrollment target sits among peer trials
59 1824th of 2000 higher than 176 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI